A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60–85 years of age
IVX-A12 was well tolerated and induced RSV- and hMPV-specific antibody responses in adults 60-85 years of age. This trial demonstrated the feasibility of an RSV/hMPV combination vaccine.
Authors
- Anastasia A. Aksyuk (ORCID: https://orcid.org/0000-0001-9778-3491)
- Max Ciarlet
- Nicholas Hourguettes
- Craig Shapiro (ORCID: https://orcid.org/0000-0002-8580-0570)
- Elizabeth M. Adams
- Judy Wen
- April E Engram
- Lee-Jah Chang
- Tope Oyedele
- Jennifer Price
- Niranjan Kanesa-thasan
- Wasima Rida
- Himanshu Bansal
- Matthew Davis
Institutions
- AstraZeneca (France) (FR)
- AstraZeneca (Switzerland) (CH)
- Sheridan Technical College (US)
- University of Rochester (US)
Publication Details
- Journal
- Vaccine
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1016/j.vaccine.2026.128345
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00